Edwards Lifesciences Corp (EW) stocks have seen investment movements from different financial entities. Ninety One UK Ltd and Ninety One North America Inc. have decreased and increased their stakes respectively, with Ninety One SA Pty Ltd also buying shares. The company's shares have been reduced by Diversify Advisory Services, KBC Group, Fisher Funds Management, Sumitomo Mitsui Trust Group, Robeco Institutional Asset Management, and Baillie Gifford & Co. Their Q4 update was met with a positive analyst view and the company is a favorite among institutional investors owning 88% of its shares. There have been predictions about the company's next quarterly earnings. Officers and VP have exercised options and sold considerable shares. Its current share price attracts various views, with an intrinsic value assessment revealing a value of $48 against the current price of $78. Despite recent share weakness, financial analysts see a bull case for Edwards Lifesciences, projecting renewed growth. Noteworthy, the company maintains a \"Moderate Buy\" rating after Q3 2025 Earnings Call showcasing notable revenue growth. The company's CFO has sold stock worth more than $1m and the VP has also traded 13k shares under a 10b5-1 plan. The company's overall guidance for 2026 indicates squeezing of profits in 2025. The narrative around Edwards Lifesciences is evolving with shifts in data and market.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Sat, 18 Apr 2026 11:43:44 GMT -
Rating 2
- Innovation -4
- Information 5
- Rumor -7
